| Completed | Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at NCT03954743 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine NCT02914184 | GlaxoSmithKline | Phase 3 |
| Completed | Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2006-2007 NCT01563146 | GlaxoSmithKline | — |
| Completed | Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2010-2011 NCT01563159 | GlaxoSmithKline | — |
| Withdrawn | Effectiveness of RotarixTM Vaccine in Children Aged Between 12 Weeks to < 5 Years, Hospitalised for Severe Gas NCT01978223 | GlaxoSmithKline | — |
| Completed | Serologic Response to Porcine Circovirus Type 1 (PCV-1) in Infants Following Administration of Rotarix™ NCT02153333 | GlaxoSmithKline | — |
| Completed | Impact on Quality of Hospital Care During Pre- and Post- Rotavirus (RV) Vaccination Introduction in Belgium NCT01592838 | GlaxoSmithKline | — |
| Completed | Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotarix Vaccination NCT01915888 | GlaxoSmithKline | — |
| Completed | A Study to Estimate the Occurrence of Rotavirus Gastroenteritis in Children < 5 Years of Age, in Bulgaria and NCT01733849 | GlaxoSmithKline | — |
| Completed | Study to Assess the Impact of Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus Gastroent NCT01733862 | GlaxoSmithKline | — |
| Completed | Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotavirus (RV) Vaccination NCT01682005 | GlaxoSmithKline | — |
| Completed | Special Drug Use Investigation for ROTARIX® NCT01636739 | GlaxoSmithKline | — |
| Completed | Drug Use Investigation for ROTARIX® NCT01636193 | GlaxoSmithKline | — |
| Completed | Observational Study on Rotavirus Gastroenteritis Epidemiology, Impact of Lyophilised vs. Liquid Formulation of NCT01435967 | GlaxoSmithKline | — |
| Completed | Epidemiological, Observational and Post Marketing Study of Rotarix™ in Children With Severe Gastroenteritis in NCT01339221 | GlaxoSmithKline | — |
| Completed | Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin Aft NCT01198769 | GlaxoSmithKline | Phase 4 |
| Completed | Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese NCT01171963 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Assess the Safety of GSK Biologicals' Liquid Human Rotavirus Vaccine in Healthy Infants NCT01107587 | GlaxoSmithKline | Phase 1 |
| Withdrawn | Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine NCT01110044 | GlaxoSmithKline | Phase 2 |
| Completed | Study to Evaluate the Safety of Rotarix™ in Chinese Children NCT01086436 | GlaxoSmithKline | Phase 1 |
| Completed | Study to Evaluate the Reactogenicity and Safety of Rotarix™ in Chinese Adults NCT01162590 | GlaxoSmithKline | Phase 1 |
| Completed | Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean Infants NCT00969228 | GlaxoSmithKline | Phase 4 |
| Completed | Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Indian I NCT00938327 | GlaxoSmithKline | — |
| Completed | Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the Uni NCT00875641 | GlaxoSmithKline | — |
| Completed | Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants NCT00779779 | GlaxoSmithKline | — |
| Completed | Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants NCT00750893 | GlaxoSmithKline | — |
| Completed | Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in Infants in Panama NCT00653198 | GlaxoSmithKline | — |
| Completed | Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized Children NCT01177826 | GlaxoSmithKline | — |
| Completed | Surveillance Study to Estimate the Proportion of Rotavirus Gastroenteritis in Children < 5 Years of Age in Rom NCT01253967 | GlaxoSmithKline | — |
| Completed | Hospital-based Surveillance to Collect Prospective Data to Estimate the Disease Burden of Severe RV GE in Swed NCT00489567 | GlaxoSmithKline | — |
| Completed | Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age NCT00533507 | GlaxoSmithKline | Phase 3 |
| Completed | Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants NCT00480324 | GlaxoSmithKline | Phase 3 |
| Completed | A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy NCT00432380 | GlaxoSmithKline | Phase 2 |
| Completed | Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Va NCT00420316 | GlaxoSmithKline | Phase 3 |
| Completed | To Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK's Oral Human Rotavirus Vaccine in Pre-Term NCT00420745 | GlaxoSmithKline | Phase 3 |
| Completed | A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within NCT00396630 | GlaxoSmithKline | Phase 3 |
| Completed | Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or 030 (NCT00197210) NCT00329745 | GlaxoSmithKline | Phase 3 |
| Completed | To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 NCT00353366 | GlaxoSmithKline | — |
| Completed | A Study in Infants to Test Two Preparations (Freeze-dried or Liquid) of the Rotavirus Vaccine (HRV Vaccine). NCT00382772 | GlaxoSmithKline | Phase 3 |
| Completed | To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination NCT00363545 | GlaxoSmithKline | Phase 3 |
| Completed | To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants NCT00345956 | GlaxoSmithKline | Phase 3 |
| Completed | Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines NCT00370318 | GlaxoSmithKline | Phase 3 |
| Completed | Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants NCT00334607 | GlaxoSmithKline | Phase 3 |
| Completed | Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rota(HRV)Vaccine in Healthy Infant NCT00289172 | GlaxoSmithKline | Phase 3 |
| Completed | Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy Afri NCT00241644 | GlaxoSmithKline | Phase 3 |
| Completed | Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus (HRV) Vaccine for the Prophyla NCT00137930 | GlaxoSmithKline | Phase 2 |
| Completed | Study of 2 Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastro NCT00134732 | GlaxoSmithKline | Phase 3 |
| Completed | A Study to Test 2 Doses of the HRV Vaccine Given With or Without OPV in Healthy Infants in Bangladesh NCT00139334 | GlaxoSmithKline | Phase 2 |
| Completed | A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa NCT00263666 | GlaxoSmithKline | Phase 2 |
| Completed | To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in C NCT00140686 | GlaxoSmithKline | Phase 3 |
| Completed | A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infa NCT00197210 | GlaxoSmithKline | Phase 3 |
| Completed | Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Inf NCT00139347 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa NCT00383903 | GlaxoSmithKline | Phase 2 |
| Completed | A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants. NCT00140673 | GlaxoSmithKline | Phase 3 |
| Completed | Assessment of Clinical Consistency of Three Production Lots of GSK Biologicals' HRV Vaccine NCT00757770 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Age NCT00385320 | GlaxoSmithKline | Phase 2 |
| Completed | Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Inf NCT00729001 | GlaxoSmithKline | Phase 2 |
| Completed | Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants NCT00425737 | GlaxoSmithKline | Phase 2 |